SynthesisClinical oral investigations2022
Resistance profiles to antifungal agents in Candida albicans isolated from human oral cavities: systematic review and meta-analysis.
Synthesis in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Candida Drug Resistance in Patients With Diabetic Foot Ulcers: A Systematic Review and Meta-Analysis.International wound journal · 2026Pooled it
- Clinical factors associated with fluconazole resistance in oral Candida from xerostomic head and neck cancer patients.Odontology · 2026Article
- Label-Free Visualization of the Antifungal Polyene Drug, Nystatin, in Biological Membranes Using Raman Microscopy.Analytical chemistry · 2026Article
- Photodynamic therapy-induced anticandidal effects via reactive oxygen species generation from bisdemethoxycurcumin and potassium iodide.Scientific reports · 2026Article
- In Vitro Activity of (-)-Myrtenol on Adherence, Morphogenesis and Lipase Activity inJournal of fungi (Basel, Switzerland) · 2026Article
- The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- Synergistic Antifungal Effects of Honokiol and Fluconazole Against Oral Candida: Implications for Managing Drug-Resistant Infections.Clinical and experimental dental research · 2026Article
- Antifungal activity of gold nanoparticles synthesized by laser ablation with blue diode laser photodynamic activation against Candida albicans.Lasers in medical science · 2026Article
- Distribution ofHealthcare (Basel, Switzerland) · 2026Review
- First Case of Candidemia With Fluconazole-ResistantCase reports in infectious diseases · 2026Article
- Assessing the vulnerability of Candida colonization through social determinants of health among college students in Puebla, Mexico.Journal of health, population, and nutrition · 2025Article
- Article
- Twenty-Year Course of Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2025Review
- Fungistatic activity and mechanism ofNarra J · 2025Article
- Aspirin Combined with Antifungal Drugs SuppressesJournal of microbiology and biotechnology · 2025Article
- Phenotypic and genotypic characterization ofJournal of oral microbiology · 2025Article
- Evaluation of Antifungal Activity AgainstHIV/AIDS (Auckland, N.Z.) · 2025Article
- Case Commentary: Extending our therapeutic range against multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- The inhibitory effects of carvacrol, nystatin, and their combination on oral candidiasis isolates.BMC research notes · 2024Article
- The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.Dermatology and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo identify the antifungal susceptibility profile of Candida spp. isolated from the human oral cavity was assessed with meta-analyses of observational studies that collected samples from the oral cavity of human subjects. MATERIAL AND
methodsIsolated Candida albicans tested by E-test®; disk diffusion test; microdilution and macrodilution; Sensititre YeastOne; and/or FungiTest. Search strategies were conducted on the MEDLINE, Embase, CINAHL, Dentistry, and Oral Sciences, Central, Scopus, and LILACS databases, and gray literature sources. Articles were initially screened by title and then their abstracts. Articles that met the conditions for inclusion were read in full, followed by data extraction. A descriptive analysis was conducted of each study, and the data were tabulated. A first meta-analysis was conducted to assess the resistance of antifungals regardless of systemic comorbidities. An additional stratified analysis was conducted by systemic comorbidity groups for the outcome "resistance" to the antifungals.
resultsWhen not grouping Candida albicans isolates by systemic conditions, the lowest resistance rates to the antifungals tested were observed for amphotericin B, nystatin, flucytosine, and caspofungin. In contrast, the highest resistance rates were observed for miconazole and econazole. There was a high degree of heterogeneity and low resistance in general in all analyses, except for the "several associated comorbidities" group, which had high resistance rates.
conclusionsClinical C. albicans isolates had low antifungal resistance. CLINICAL RELEVANCE: The presence of concomitant systemic comorbidities appears to be an essential factor that should be considered when evaluating resistance to antifungals for oral isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.